Marex Group’s Royalty Pharma RPRX Stock Holding History

Marex Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,500	Closed	-$483K	–	1230
2025 Q4	$483K	Buy	+12,500	New	+$477K	﹤0.01%	572

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Marex Group's RPRX Position: Q1 2026 in Review

Marex Group sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 12,500 shares — an estimated $483K sold.

Marex Group first reported a position in RPRX in Q4 2025 and held it in 1 quarter. The position peaked at $483K in Q4 2025. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Marex Group reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Marex Group sold 12,500 Royalty Pharma shares in Q1 2026, an estimated $483K.
Marex Group first reported a position in Royalty Pharma in Q4 2025 and held it in 1 quarter.
Marex Group's Royalty Pharma position peaked at $483K in Q4 2025.
592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.